GW Pharma Looks Forward To EU Epidyolex Launch
Anticipating pan-EU approval of Epidyolex within the next six months, GW Pharmaceuticals is gearing up to launch what would be the first plant-derived cannabinoid medicine to be approved under the EU centralized procedure.
You may also be interested in...
Five new medicines, including what could become Europe’s first ever tumor-agnostic cancer treatment, have been recommended for approval by the European Medicines Agency.
Seven new medicines, including GW Pharma's orphan cannabidiol product, Epidyolex, are due for an opinion from the European Medicines Agency this week on whether they should be recommended for pan-EU approval.
Four drugs are up for an opinion this week on whether they should be granted EU-wide approval, including Amgen/UCB's osteoporosis drug romosozumab.